Pay in 4 interest-free payments of $6.04 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
In particular, the TRIUMPH-1 Phase 3 results revealed an impressive average weight loss of up to 28.3% over 80 weeks, showcasing Retatrutide as a promising treatment compared to existing options like tirzepatide, known as Zepbound when used for weight loss
Here are some recent targets: Seamus Fernandez from Guggenheim set a target price of $1183.0 on 04/22/2026 Terence Flynn from Morgan Stanley set a target price of $1327.0 on 04/10/2026 Jason Gerberry from B of A Securities set a target price of $1294.0 on 04/02/2026 Rajesh Kumar from HSBC set a target price of $850.0 on 03/17/2026 Trung Huynh from RBC Capital set a target price of $1250.0 on 02/25/2026 Emily Field from Barclays set a target price of $1350.0 on 02/20/2026 James Shin from Deutsche Bank set a target price of $1285.0 on 02/09/2026 This article is not financial advice
If yes, Hims is the right one, because Peak is compounded only
doi:10.1056/NEJMoa2501006 McGuire DK, Marx N, Mulvagh SL, et al
US$ 20.74
US$ 29.45
US$ 25.99
US$ 24.55
US$ 24.49
US$ 24.50
US$ 25.71
US$ 21.01
